Axsome Therapeutics (AXSM) Expected to Release Quarterly Earnings on Monday

Axsome Therapeutics (NASDAQ:AXSM) will likely be announcing its Q2 2026 results before the market opens on Monday, August 10th. Analysts expect the company to post earnings of ($0.8921) per share and revenue of $221.1140 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Monday, August 10, 2026 at 8:00 AM ET.

Axsome Therapeutics Price Performance

Shares of Axsome Therapeutics stock opened at $212.74 on Friday. The firm has a market cap of $10.95 billion, a PE ratio of -57.03 and a beta of 0.65. The stock has a 50 day moving average of $236.95 and a 200 day moving average of $203.96. The company has a current ratio of 1.39, a quick ratio of 1.32 and a debt-to-equity ratio of 2.27. Axsome Therapeutics has a 12 month low of $102.67 and a 12 month high of $260.19.

Analysts Set New Price Targets

Several brokerages recently commented on AXSM. Wells Fargo & Company upped their price target on shares of Axsome Therapeutics from $225.00 to $255.00 and gave the company an “overweight” rating in a report on Tuesday, May 5th. Cantor Fitzgerald reissued an “overweight” rating and issued a $272.00 price objective on shares of Axsome Therapeutics in a research note on Monday, May 4th. Piper Sandler restated an “overweight” rating and set a $258.00 target price on shares of Axsome Therapeutics in a research report on Monday, May 4th. Jefferies Financial Group reaffirmed a “buy” rating and set a $380.00 target price on shares of Axsome Therapeutics in a research note on Thursday, June 11th. Finally, Oppenheimer set a $280.00 price target on Axsome Therapeutics in a report on Monday, May 4th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $265.55.

Insider Activity at Axsome Therapeutics

In related news, CEO Herriot Tabuteau sold 49,670 shares of the firm’s stock in a transaction dated Tuesday, June 9th. The shares were sold at an average price of $241.01, for a total value of $11,970,966.70. Following the transaction, the chief executive officer owned 7,229 shares of the company’s stock, valued at $1,742,261.29. This trade represents a 87.30% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Mark Coleman sold 6,000 shares of Axsome Therapeutics stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $230.30, for a total transaction of $1,381,800.00. Following the sale, the director owned 35,140 shares of the company’s stock, valued at $8,092,742. The trade was a 14.58% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 200,766 shares of company stock worth $46,685,646. 20.60% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Price T Rowe Associates Inc. MD raised its position in Axsome Therapeutics by 45.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,509,870 shares of the company’s stock valued at $275,763,000 after purchasing an additional 472,422 shares in the last quarter. Wellington Management Group LLP lifted its holdings in shares of Axsome Therapeutics by 84.1% in the 3rd quarter. Wellington Management Group LLP now owns 1,334,560 shares of the company’s stock worth $162,082,000 after buying an additional 609,516 shares during the period. Invesco Ltd. grew its position in shares of Axsome Therapeutics by 28.6% during the 4th quarter. Invesco Ltd. now owns 1,273,494 shares of the company’s stock worth $232,591,000 after buying an additional 282,937 shares in the last quarter. State Street Corp grew its position in shares of Axsome Therapeutics by 5.8% during the 2nd quarter. State Street Corp now owns 958,503 shares of the company’s stock worth $100,058,000 after buying an additional 52,483 shares in the last quarter. Finally, Deep Track Capital LP increased its stake in shares of Axsome Therapeutics by 12.3% during the third quarter. Deep Track Capital LP now owns 900,000 shares of the company’s stock valued at $109,305,000 after buying an additional 98,629 shares during the period. Institutional investors own 81.49% of the company’s stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.